Skip to main content

Advertisement

SpringerLink
Log in

Response and survival in advanced carcinoma without severe antitumor drug toxicity

  • Published:
Diseases of the Colon & Rectum

Summary

5-FU is a useful, fairly predictable drug for the palliation of advanced colonic carcinoma. When used with caution, subjective improvement can be expected in more than half the patients and objective remissions in a sixth to a quarter. Toxic side-effects can be kept to a minimum by evaluating the patient carefully before each dose of the drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ansfield, F. J.: Further clinical comparison between 5-fluoro-2′-deoxyuridine (5-FUDR) and 5-fluorouracil (5-FU) (abstr.). Amer. Ass. Cancer Res. Proc.4: 2 (Apr.) 1963.

    Google Scholar 

  2. Eastern Cooperative Group in Solid Tumor Chemotherapy: Comparison of antimetabolites in the treatment of breast and colon cancer. J.A.M.A.200: 770, 1967.

    Google Scholar 

  3. Hall, T. C., J. A. Cavins, C. L. Khung, C. T. Griffiths, M. M. Dederick, and W. J. Yount: Time and vehicle studies of a safe and effective method for administration of 5-fluorouracil. Cancer19: 1008, 1966.

    Article  PubMed  CAS  Google Scholar 

  4. Khung, C. L., T. C. Hall, A. J. Piro, and M. M. Dederick: A clinical trial of oral 5-fluorouracil. Clin. Pharmacol. Ther.7: 527, 1966.

    PubMed  CAS  Google Scholar 

  5. McSherry, C. K., G. N. Cornell, and F. Glenn: Carcinoma of the colon and rectum. Ann. Surg.169: 502, 1969.

    Article  PubMed  CAS  Google Scholar 

  6. Moertel, C. G., and R. J. Reitemeier: Advanced Gastrointestinal Cancer/Clinical Management and Chemotherapy. New York, Hoeber Medical Division, Harper & Row, Publishers, 1969, 218 pp.

    Google Scholar 

  7. Nahhas, W. A., T. C. Hall, C. D. Sherman, Jr., and E. D. Savlov: Antitumor drug toxicity: Implications for response and for survival. Amer. J. Med. Sci.258: 245, 1969.

    Article  PubMed  CAS  Google Scholar 

  8. Ramirez, G., B. C. Korbitz, H. L. Davis, Jr., and F. J. Ansfield: Comparative study of monthly courses versus weekly doses of 5-fluorouracil (NSC-19893). Cancer Chemother. Rep.53: 243, 1969.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Departments of Surgery and Medicine, Division of Oncology, University of Rochester School of Medicine and Dentistry, Rochester, New York

    Edwin D. Savlov M.D., Charles D. Sherman Jr. M.D., Thomas C. Hall M.D. & William A. Nahhas M.D.

Authors
  1. Edwin D. Savlov M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charles D. Sherman Jr. M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas C. Hall M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William A. Nahhas M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Read at the meeting of the American Proctologic Society, Hollywood, Florida, April 12 to 16, 1970.

Supported in part by U. S. P. H. S. Grant CA 11083 and Grant CDEP 2-R10-Ca-06071-08.

About this article

Cite this article

Savlov, E.D., Sherman, C.D., Hall, T.C. et al. Response and survival in advanced carcinoma without severe antitumor drug toxicity. Dis Colon Rectum 13, 421–424 (1970). https://doi.org/10.1007/BF02616784

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02616784

Keywords

Search

Navigation